Alpha-1 antitrypsin deficiency
inherited emphysema · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Alpha-1 antitrypsin deficiency is an inherited cause of early-onset, basal-predominant emphysema and liver disease, classically in the ZZ phenotype. Testing is recommended in COPD/emphysema especially when early-onset, minimal smoking, basal distribution or positive family history.
Red flags
- Rapid FEV1 decline in a young patient
- Hepatic decompensation or hepatocellular carcinoma features
- Haemoptysis / new mass (exclude cancer)
- Severe hypoxaemia / cor pulmonale
Assessment
Differential diagnosis
- Smoking-related COPD/emphysema
- Bronchiectasis
- Asthma
- Other causes of panacinar emphysema
- Chronic liver disease of other cause
Investigations
- Serum alpha-1 antitrypsin level
- Phenotyping/genotyping (e.g. PiZZ, PiSZ)
- Spirometry with reversibility and gas transfer
- HRCT chest (basal panacinar emphysema, bronchiectasis)
- Liver function tests and liver assessment
- Family screening and counselling
Management
- Suspect in emphysema that is early-onset, basal, in non/light smokers or with family history
- Measure serum alpha-1 antitrypsin level and confirm with phenotype/genotype
- Assess lung involvement with spirometry, gas transfer and HRCT
- Evaluate liver involvement with LFTs and imaging
- Advise strict smoking avoidance and minimise occupational/environmental exposures
- Treat airflow obstruction with standard inhaled COPD therapy and pulmonary rehabilitation
- Vaccinate and manage exacerbations promptly
- Consider intravenous alpha-1 antitrypsin augmentation therapy in selected patients with emphysema
- Screen and counsel family members and offer genetic counselling
- Refer advanced lung disease for transplant and monitor for liver complications
Drugs & doses
Alpha-1 antitrypsin augmentation: pooled human alpha-1 proteinase inhibitor 60 mg/kg IV once weekly (selected emphysema patients)
Standard inhaled therapy e.g. LABA-LAMA +/- ICS per phenotype
Smoking-cessation pharmacotherapy
Vaccination (influenza, pneumococcal, COVID-19, hepatitis for liver protection)
Disposition
Specialist respiratory / alpha-1 service; hepatology for liver disease; family screening and transplant assessment for advanced disease.
Complications & pitfalls
- Progressive emphysema and respiratory failure
- Cirrhosis and hepatocellular carcinoma
- Bronchiectasis
- Panniculitis and (rarely) vasculitis
Exam pearls
- Smoking dramatically accelerates lung destruction — cessation is the single most important intervention
- Emphysema is classically basal and panacinar, in contrast to upper-zone smoking emphysema
- Augmentation therapy slows CT-measured emphysema progression but not all guidelines endorse it
- Liver disease arises from polymer accumulation, independent of the lung disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.